EUVIMEDEUVIMED entdecken
Crossref

Personalized treatment of the non-responder population: The biggest unmet clinical demand in precision medicine

Shu-Ti Lin, Sharon S. Yeh, Chen Yeh

INNOSC Theranostics and Pharmacological Sciences · 15.07.2026 · 9 (2) · 026090008

DOI: 10.36922/itps026090008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift INNOSC Theranostics and Pharmacological Sciences, online erschienen am 15.07.2026. Verfasst von Shu-Ti Lin und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current approaches to therapy design and treatment strategies fall short in addressing a critical challenge of precision medicine: only a small fraction of treated patients respond to precision-targeted drugs. An even more concerning limitation is our present inability to predict drug responses for non-responders—especially in life-threatening conditions such as aggressive cancers, where negative biomarker results may leave insufficient time to pursue alternative treatments. Consequently, accurately predicting therapeutic responses in these high-risk patients or identifying optimal candidates for specific therapies remains a pressing and unresolved clinical need. For years, clinicians have grappled with a fundamental question: Why do some patients experience dramatic—sometimes complete—clinical responses, while most see little to no benefit? The challenge lies in identifying non-responders early and determining what interventions could convert them into responders. Emerging research is now shedding light on why certain cancer patients fail to respond to precision therapies, offering hope for guiding patients and physicians toward more effective treatments. One particularly promising frontier is the use of gene–drug mapping technologies, which could revolutionize care by transforming non-responders into responders. Additionally, understanding the interplay between cancer cells and the immune system may unlock the full potential of precision medicine, bringing us closer to effective therapies for every cancer patient.

Zitieren

APA

Lin, S., Yeh, S. S., & Yeh, C. (2026). Personalized treatment of the non-responder population: The biggest unmet clinical demand in precision medicine. INNOSC Theranostics and Pharmacological Sciences, 9(2), 026090008. https://doi.org/10.36922/itps026090008

Vancouver

Lin S, Yeh SS, Yeh C. Personalized treatment of the non-responder population: The biggest unmet clinical demand in precision medicine. INNOSC Theranostics and Pharmacological Sciences. 2026;9(2):026090008. doi:10.36922/itps026090008

BibTeX
@article{Lin2026,
  author = {Lin, Shu-Ti and Yeh, Sharon S. and Yeh, Chen},
  title = {Personalized treatment of the non-responder population: The biggest unmet clinical demand in precision medicine},
  journal = {INNOSC Theranostics and Pharmacological Sciences},
  year = {2026},
  volume = {9},
  number = {2},
  pages = {026090008},
  doi = {10.36922/itps026090008}
}
Kostenlos starten →